LEADS BIOLABS-B's Novel Cancer Therapy LBL-024 Granted Priority Review in China for Advanced Neuroendocrine Carcinoma

Stock News12:34

The biologics license application for LEADS BIOLABS-B's (ASX: 09887) investigational drug, VELIXIN™ (the PD-L1/4-1BB bispecific antibody oplitelimab, LBL-024), as a monotherapy for advanced extrapulmonary neuroendocrine carcinoma has been accepted into the priority review and approval pathway by China's National Medical Products Administration Center for Drug Evaluation.

This BLA submission is supported by positive results from a pivotal registration clinical study led by Professor Lin Shen from Beijing Cancer Hospital, which evaluated the efficacy and safety of VELIXIN™ in patients with advanced EP-NEC who had progressed after at least two prior lines of systemic therapy.

Under relevant Chinese regulations, the review timeline for a BLA accepted into the priority pathway is 130 working days, compared to 200 working days for the standard review procedure.

The inclusion of VELIXIN™ in the priority review program represents a significant milestone on its path to commercialization, providing clear guidance and certainty regarding its anticipated approval timeline.

The company is actively advancing pre-commercialization preparations related to the product's potential launch.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1114500368?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-10 12:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1114500368","market":"sh","top_or_hot":-1,"title":"LEADS BIOLABS-B's Novel Cancer Therapy LBL-024 Granted Priority Review in China for Advanced Neuroendocrine Carcinoma","media":"Stock News","content":"<p>The biologics license application for <b>LEADS BIOLABS-B</b>'s (<b>ASX: 09887</b>) investigational drug, VELIXIN™ (the PD-L1/4-1BB bispecific antibody oplitelimab, LBL-024), as a monotherapy for advanced extrapulmonary neuroendocrine carcinoma has been accepted into the priority review and approval pathway by China's National Medical Products Administration Center for Drug Evaluation.<br><br>This BLA submission is supported by positive results from a pivotal registration clinical study led by Professor Lin Shen from Beijing Cancer Hospital, which evaluated the efficacy and safety of VELIXIN™ in patients with advanced EP-NEC who had progressed after at least two prior lines of systemic therapy.<br><br>Under relevant Chinese regulations, the review timeline for a BLA accepted into the priority pathway is 130 working days, compared to 200 working days for the standard review procedure.<br><br>The inclusion of VELIXIN™ in the priority review program represents a significant milestone on its path to commercialization, providing clear guidance and certainty regarding its anticipated approval timeline.<br><br>The company is actively advancing pre-commercialization preparations related to the product's potential launch.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LEADS BIOLABS-B's Novel Cancer Therapy LBL-024 Granted Priority Review in China for Advanced Neuroendocrine Carcinoma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLEADS BIOLABS-B's Novel Cancer Therapy LBL-024 Granted Priority Review in China for Advanced Neuroendocrine Carcinoma\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-10 12:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>The biologics license application for <b>LEADS BIOLABS-B</b>'s (<b>ASX: 09887</b>) investigational drug, VELIXIN™ (the PD-L1/4-1BB bispecific antibody oplitelimab, LBL-024), as a monotherapy for advanced extrapulmonary neuroendocrine carcinoma has been accepted into the priority review and approval pathway by China's National Medical Products Administration Center for Drug Evaluation.<br><br>This BLA submission is supported by positive results from a pivotal registration clinical study led by Professor Lin Shen from Beijing Cancer Hospital, which evaluated the efficacy and safety of VELIXIN™ in patients with advanced EP-NEC who had progressed after at least two prior lines of systemic therapy.<br><br>Under relevant Chinese regulations, the review timeline for a BLA accepted into the priority pathway is 130 working days, compared to 200 working days for the standard review procedure.<br><br>The inclusion of VELIXIN™ in the priority review program represents a significant milestone on its path to commercialization, providing clear guidance and certainty regarding its anticipated approval timeline.<br><br>The company is actively advancing pre-commercialization preparations related to the product's potential launch.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HK0000500386.USD","symbol_name":"易方达 (香港) 中国股票股息基金A 类 (累积) 美元","start_time":0,"source_url":"","article_id":"1114500368","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1114500368","pubTimestamp":1783658060,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"The biologics license application for LEADS BIOLABS-B's (ASX: 09887) investigational drug, VELIXIN™ (the PD-L1/4-1BB bispecific antibody oplitelimab, LBL-024), as a monotherapy for advanced...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HK0000500386.USD":"易方达 (香港) 中国股票股息基金A 类 (累积) 美元","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","HK0000252152.HKD":"易方达 (香港) 中国股票股息基金A 类 (累积) 港元","09887":"维立志博-B","HK0000252160.HKD":"易方达 (香港) 中国股票股息基金A 类 (分派) 港元","PD":"PagerDuty, Inc.","BK1161":"生物科技","BK4023":"应用软件"},"translate_title":"LEADS BIOLABS-B 新型癌症疗法 LBL-024 在中国获得晚期神经内分泌癌优先审查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09887":1,"PD":1},"content_text":"The biologics license application for LEADS BIOLABS-B's (ASX: 09887) investigational drug, VELIXIN™ (the PD-L1/4-1BB bispecific antibody oplitelimab, LBL-024), as a monotherapy for advanced extrapulmonary neuroendocrine carcinoma has been accepted into the priority review and approval pathway by China's National Medical Products Administration Center for Drug Evaluation.This BLA submission is supported by positive results from a pivotal registration clinical study led by Professor Lin Shen from Beijing Cancer Hospital, which evaluated the efficacy and safety of VELIXIN™ in patients with advanced EP-NEC who had progressed after at least two prior lines of systemic therapy.Under relevant Chinese regulations, the review timeline for a BLA accepted into the priority pathway is 130 working days, compared to 200 working days for the standard review procedure.The inclusion of VELIXIN™ in the priority review program represents a significant milestone on its path to commercialization, providing clear guidance and certainty regarding its anticipated approval timeline.The company is actively advancing pre-commercialization preparations related to the product's potential launch.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1114500368","isCrawlerRequest":true}